SCHEMBL20985392

SCHEMBL20985392

Nc1nc2cc(CO)ccc2n1[C@H]1CC[C@@H](C(=O)O)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKACA P17612 1/20 0.49
▸ RPS6KB1 P23443 1/20 0.49
▸ IRAK4 Q9NWZ3 2/20 0.43
▸ LMNA P02545 1/20 0.41
▸ ACSL1 P33121 3/20 0.39
▸ SPR P35270 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.37
▸ RPS6KA5 O75582 1/20 0.35
▸ BRD4 O60885 4/20 0.35
▸ CREBBP Q92793 4/20 0.35
▸ CCR5 P51681 1/20 0.35
▸ MAP3K7 O43318 1/20 0.35
▸ ALK Q9UM73 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ GFER P55789 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20985390 1.00 PRKACA (0.49) PRKACARPS6KB1IRAK4LMNAACSL1
SCHEMBL2033562 0.85 PRKACA (0.53) PRKACARPS6KB1IRAK4RPS6KA5MAP3K7
SCHEMBL2033557 0.85 PRKACA (0.53) PRKACARPS6KB1IRAK4RPS6KA5MAP3K7
SCHEMBL20985345 0.85 SPR (0.55) IRAK4LMNASPRMAP3K7ALK
SCHEMBL29937671 0.85 PRKACA (0.49) PRKACARPS6KB1IRAK4LMNAL3MBTL1
SCHEMBL21025771 0.85 PRKACA (0.49) PRKACARPS6KB1IRAK4LMNAL3MBTL1
SCHEMBL21025907 0.85 PRKACA (0.49) PRKACARPS6KB1IRAK4LMNAL3MBTL1
SCHEMBL20985344 0.85 SPR (0.55) IRAK4LMNASPRMAP3K7ALK
SCHEMBL2027616 0.84 PRKACA (0.60) PRKACARPS6KB1IRAK4L3MBTL1RPS6KA5
SCHEMBL20985370 0.83 SMN1; SMN2 (0.46) IRAK4LMNASPRL3MBTL1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 — — US disclosed
US-11065231-B2 Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2021-07-20 — — US disclosed
EP-3710443-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES Arvinas Operations, Inc. (US) 2020-09-23 — — EP disclosed
US-20190151295-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES ARVINAS OPERATIONS, INC. 2019-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190151295-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES IRAK1, IRAK4, IRAK2 PRKACA 415/4885RPS6KB1 516/4885IRAK4 2/4885
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides IRAK1, IRAK4, IRAK2 PRKACA 213/4885RPS6KB1 443/4885IRAK4 2/4885
US-11065231-B2 Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides IRAK1, IRAK4, IRAK2 PRKACA 415/4885RPS6KB1 516/4885IRAK4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback